Tachyon Therapeutics, Inc.

About Tachyon Therapeutics, Inc.

Tachyon Therapeutics is focused on accelerating the development of first-in-class therapeutics against significant new drug targets to fight cancer. Their mission is to target new pathways at the core tumorigenic mechanisms using a deep scientific foundation in molecular cancer biology, tumorigenesis, and cancer stem cell biology.

Products & Services

TACH101:A first-in-class KDM4 inhibitor targeting epigenetic regulation for the treatment of advanced solid tumors.

KDM4 Program:Focuses on KDM4, an epigenetic regulator controlling gene expression, cell proliferation, stem cell maintenance, apoptosis, and metastasis in cancer.

TGF-β Superfamily Antibody Therapeutic:A novel antibody therapeutic developed in collaboration with AbCellera for the treatment of cancer.

Specialties

Molecular Cancer Biology Tumorigenesis Cancer Stem Cell Biology Epigenetic Regulation (KDM4) Preclinical and Clinical Drug Development Advanced Cancer Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 7100000 MR: - FA: 7.1 million FAN: 7100000	D: 2023-03-01 FD: 2023-03-01	1 investors

Grant Latest

2023-03-01

$7.1M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stephen Quake

Serial Entrepreneur

M

Michael Clarke

Serial Entrepreneur

Recent News